Hosted on MSN17d
Maxim Group Initiates Coverage of Kazia Therapeutics Limited - Depositary Receipt () (KZIA) with Buy RecommendationAs of January 28, 2025, the average one-year price target for Kazia Therapeutics Limited - Depositary Receipt is $19.48/share. The forecasts range from a low of $19.29 to a high of $20.06.
An Ontario lottery player has hit the Lotto Max jackpot, winning a staggering $20 million prize. Stoney Creek resident Anna Pelka has played the lottery with the Ontario Lottery and Gaming Corporation ...
Anna Pelka from Stoney Creek won a $20 million Lotto Max jackpot from Dec. 20, 2024, after purchasing a quick pick ticket on her way home from work (Photo Courtesy OLG). Share this story ...
We recently compiled a list of the 10 Best ASX Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Kazia Therapeutics Limited (NASDAQ:KZIA) stands against ...
1 Day KZIA -16.84% DJIA -0.75% Russell 2K -0.86% Health Care/Life Sciences -0.88% ...
In this article, we are going to take a look at where Kazia Therapeutics Limited (NASDAQ:KZIA) stands against other best ASX stocks to buy according to hedge funds. According to a report by the ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Kazia Therapeutics has announced the regulatory approval and launch of its new clinical trial evaluating the combination of paxalisib and immunotherapy in patients with advanced breast cancer.
Researchers from QIMR Berghofer Medical Research Institute in collaboration with Kazia Therapeutics have designed a drug called Paxalisib to combat metastatic triple negative breast cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results